Lilly invites outside researchers to submit compounds
This article was originally published in Scrip
Executive Summary
Lilly has launched a web portal to solicit and evaluate potential drug candidates in Alzheimer's disease, cancer, diabetes and osteoporosis. The Lilly Phenotypic Drug Discovery Initiative, or PD2, will allow the company to work with outside institutions and scientists with whom it has not previously collaborated on drug discovery.